|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ioannou N, Seddon AM, Dalgleish A,
Mackintosh D and Modjtahedi H: Expression pattern and targeting of
HER family members and IGF-IR in pancreatic cancer. Front Biosci
(Landmark Ed). 17:2698–2724. 2012. View
Article : Google Scholar
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
4
|
Alberts SR, Gores GJ, Kim GP, Roberts LR,
Kendrick ML, Rosen CB, Chari ST and Martenson JA: Treatment options
for hepatobiliary and pancreatic cancer. Mayo Clin Proc.
82:628–637. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997.PubMed/NCBI
|
|
6
|
Thota R, Pauff JM and Berlin JD: Treatment
of metastatic pancreatic adenocarcinoma: A review. Oncology
(Williston Park). 28:70–74. 2014.
|
|
7
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al;
National Cancer Institute of Canada Clinical Trials Group.
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kelley RK and Ko AH: Erlotinib in the
treatment of advanced pancreatic cancer. Biologics. 2:83–95.
2008.PubMed/NCBI
|
|
9
|
Modjtahedi H and Dean C: The receptor for
EGF and its ligands - expression, prognostic value and target for
therapy in cancer (Review). Int J Oncol. 4:277–296. 1994.PubMed/NCBI
|
|
10
|
Chong CR and Jänne PA: The quest to
overcome resistance to EGFR-targeted therapies in cancer. Nat Med.
19:1389–1400. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garrido-Laguna I and Hidalgo M: Pancreatic
cancer: From state-of-the-art treatments to promising novel
therapies. Nat Rev Clin Oncol. 12:319–334. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ioannou N, Dalgleish AG, Seddon AM,
Mackintosh D, Guertler U, Solca F and Modjtahedi H: Anti-tumour
activity of afatinib, an irreversible ErbB family blocker, in human
pancreatic tumour cells. Br J Cancer. 105:1554–1562. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Modjtahedi H, Cho BC, Michel MC and Solca
F: A comprehensive review of the preclinical efficacy profile of
the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs
Arch Pharmacol. 387:505–521. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ioannou N, Seddon AM, Dalgleish A,
Mackintosh D and Modjtahedi H: Treatment with a combination of the
ErbB (HER) family blocker afatinib and the IGF-IR inhibitor,
NVP-AEW541 induces synergistic growth inhibition of human
pancreatic cancer cells. BMC Cancer. 13:412013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cunningham MP, Thomas H, Fan Z and
Modjtahedi H: Responses of human colorectal tumor cells to
treatment with the anti-epidermal growth factor receptor monoclonal
antibody ICR62 used alone and in combination with the EGFR tyrosine
kinase inhibitor gefitinib. Cancer Res. 66:7708–7715. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Solca F: Pharmacology and molecular
mechanisms of BIBW2992 a potent irreversible dual EGFR/HER-2 kinase
inhibitor of cancer therapy. Target Oncol. 2:s152007.
|
|
17
|
García-Echeverría C, Pearson MA, Marti A,
Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG,
Cozens R, et al: In vivo antitumor activity of NVP-AEW541-A novel,
potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell.
5:231–239. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim MP and Gallick GE: Gemcitabine
resistance in pancreatic cancer: Picking the key players. Clin
Cancer Res. 14:1284–1285. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakano Y, Tanno S, Koizumi K, Nishikawa T,
Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T and Kohgo
Y: Gemcitabine chemoresistance and molecular markers associated
with gemcitabine transport and metabolism in human pancreatic
cancer cells. Br J Cancer. 96:457–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morgillo F, Cantile F, Fasano M, Troiani
T, Martinelli E and Ciardiello F: Resistance mechanisms of tumour
cells to EGFR inhibitors. Clin Transl Oncol. 11:270–275. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin L and Bivona TG: Mechanisms of
resistance to epidermal growth factor receptor inhibitors and novel
therapeutic strategies to overcome resistance in NSCLC patients.
Chemother Res Pract. 2012:8172972012.PubMed/NCBI
|
|
23
|
Yu Z, Pestell TG, Lisanti MP and Pestell
RG: Cancer stem cells. Int J Biochem Cell Biol. 44:2144–2151. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lage H: An overview of cancer multidrug
resistance: A still unsolved problem. Cell Mol Life Sci.
65:3145–3167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dean M: ABC transporters, drug resistance,
and cancer stem cells. J Mammary Gland Biol Neoplasia. 14:3–9.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lonardo E, Hermann PC and Heeschen C:
Pancreatic cancer stem cells - update and future perspectives. Mol
Oncol. 4:431–442. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Simeone DM: Pancreatic cancer stem cells:
Implications for the treatment of pancreatic cancer. Clin Cancer
Res. 14:5646–5648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Marhaba R and Zöller M: CD44 in cancer
progression: Adhesion, migration and growth regulation. J Mol
Histol. 35:211–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sherman LS, Rizvi TA, Karyala S and Ratner
N: CD44 enhances neuregulin signaling by Schwann cells. J Cell
Biol. 150:1071–1084. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bourguignon LYW, Zhu H, Zhou B, Diedrich
F, Singleton PA and Hung MC: Hyaluronan promotes CD44v3-Vav2
interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling
during ovarian tumor cell migration and growth. J Biol Chem.
276:48679–48692. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ozasa H, Oguri T, Maeno K, Takakuwa O,
Kunii E, Yagi Y, Uemura T, Kasai D, Miyazaki M and Niimi A:
Significance of c-MET overexpression in cytotoxic anticancer
drug-resistant small-cell lung cancer cells. Cancer Sci.
105:1032–1039. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hage C, Rausch V, Giese N, Giese T,
Schönsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J and Herr
I: The novel c-Met inhibitor cabozantinib overcomes gemcitabine
resistance and stem cell signaling in pancreatic cancer. Cell Death
Dis. 4:e6272013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Y and Fu L: Mechanisms of acquired
resistance to tyrosine kinase inhibitors. Acta Pharm Sin B.
1:197–207. 2011. View Article : Google Scholar
|
|
37
|
Moschetta M, Basile A, Ferrucci A,
Frassanito MA, Rao L, Ria R, Solimando AG, Giuliani N, Boccarelli
A, Fumarola F, et al: Novel targeting of phospho-cMET overcomes
drug resistance and induces antitumor activity in multiple myeloma.
Clin Cancer Res. 19:4371–4382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bardelli A, Corso S, Bertotti A, Hobor S,
Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A,
Zecchin D, et al: Amplification of the MET receptor drives
resistance to anti-EGFR therapies in colorectal cancer. Cancer
Discov. 3:658–673. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and
Settleman J: Drug resistance via feedback activation of Stat3 in
oncogene-addicted cancer cells. Cancer Cell. 26:207–221. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Alas S and Bonavida B: Inhibition of
constitutive STAT3 activity sensitizes resistant non-Hodgkin's
lymphoma and multiple myeloma to chemotherapeutic drug-mediated
apoptosis. Clin Cancer Res. 9:316–326. 2003.PubMed/NCBI
|
|
41
|
Wu K, Chang Q, Lu Y, Qiu P, Chen B, Thakur
C, Sun J, Li L, Kowluru A and Chen F: Gefitinib resistance resulted
from STAT3-mediated Akt activation in lung cancer cells.
Oncotarget. 4:2430–2438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tang J, Guo F, Du Y, Liu X, Qin Q, Liu X,
Yin T, Jiang L and Wang Y: Continuous exposure of non-small cell
lung cancer cells with wild-type EGFR to an inhibitor of EGFR
tyrosine kinase induces chemoresistance by activating STAT3. Int J
Oncol. 46:2083–2095. 2015.PubMed/NCBI
|
|
43
|
Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F,
Ha SJ, Soo RA, Christensen JG, Lee JH and Cho BC: Activation of
IL-6R/JAK1/STAT3 signaling induces de novo resistance to
irreversible EGFR inhibitors in non-small cell lung cancer with
T790M resistance mutation. Mol Cancer Ther. 11:2254–2264. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fofaria NM and Srivastava SK: STAT3
induces anoikis resistance, promotes cell invasion and metastatic
potential in pancreatic cancer cells. Carcinogenesis. 36:142–150.
2015. View Article : Google Scholar :
|
|
45
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sen M, Joyce S, Panahandeh M, Li C, Thomas
SM, Maxwell J, Wang L, Gooding WE, Johnson DE and Grandis JR:
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin
Cancer Res. 18:4986–4996. 2012. View Article : Google Scholar : PubMed/NCBI
|
